Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Northwest Biotherapeutics Inc

+ Add to Watchlist

NBYA:GR

7.996 EUR 0.190 2.43%

As of 11:20:51 ET on 04/24/2015.

Snapshot for Northwest Biotherapeutics Inc (NBYA)

Open: 7.803 Day's Range: 7.773 - 8.088 Volume: 1,450
Previous Close: 7.806 52wk Range: 2.963 - 8.690 1-Yr Rtn: +88.27%

Stock Chart for NBYA

No chart data available.
  • NBYA:GR 7.996
  • 1D
  • 1M
  • 1Y
7.806
Interactive NBYA Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NBYA

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -
Est. PEG Ratio -
Market Cap (M EUR) 562.20
Shares Outstanding (M) 70.31
30 Day Average Volume 996
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/15/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NBYA

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NBYA

Northwest Biotherapeutics, Inc., a biotechnology company, discovers, develops, and commercializes immunotherapy products. The Company's products generate and enhance immune system responses to treat cancer. The DCVax product candidate platform creates cancer immunotherapies.

Linda F PowersChairman/President/CEOMarnix L BoschChief Technology Officer
Alton L BoyntonChief Scientific OfficerAnthony E Maida IIISenior VP:Clinical Research
More Company Profile & Key Executives for NBYA

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil